Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma
Vascular endothelial growth factors receptors (VEGFR) inhibitors play a vital role in the treatment of renal cell carcinoma. These are small molecules that predominantly exhibit anti-angiogenesis activity in conjunction with other anti-tumor effects. These drug therapies are approved for the use in...
Main Authors: | Jie Yi Tan, Aadya Jaipuria, Ronny Priefer |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Ahmad Dahlan
2023-07-01
|
Series: | Pharmaciana |
Subjects: | |
Online Access: | http://journal.uad.ac.id/index.php/PHARMACIANA/article/view/24638/pdf_283 |
Similar Items
-
Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
by: Qian Zhang, et al.
Published: (2020-06-01) -
Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
by: Christopher Kwok, et al.
Published: (2023-07-01) -
Editorial: Immune checkpoint inhibitors in renal cell carcinoma
by: Scott S. Tykodi, et al.
Published: (2023-04-01) -
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
by: Shigeo Shimose, et al.
Published: (2022-09-01) -
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021-01-01)